The leader in engineered macrophages

Engineered macrophages are key drivers of both innate and adaptive immune responses. Our proprietary platform addresses the challenges of other cell therapies targeting solid tumors. With an emerging pipeline of oncology CAR-Macrophages, we are prepared to lead the fight against cancer and revolutionize the field of immunotherapy.

Current Portfolio Discovery | Preclinical | Phase 1
CT – 0508 (CAR-Macrophage)
Discovery | Preclinical | Phase 1
CT – 0508 + Pembro (CAR-Macrophage)
Discovery | Preclinical | Phase 1
CT – 0525 (CAR-Monoctye)
Discovery | Preclinical | Phase 1
CT – 1119 (Mesothelin)
Discovery | Preclinical | Phase 1
CT – 0729 (PSMA)
Discovery | Preclinical | Phase 1
In-Vivo mRNA CAR-M
Discovery | Preclinical | Phase 1

A pioneer in next-generation cell therapies

With our proprietary platform, we see an opportunity for:

Effective Gene




Our differentiated approach to engineered cell therapies

Hear from CEO Steven Kelly on the promise and potential of Carisma’s proprietary platform.

The Latest News

See how the power of macrophages is harnessed to make life-changing progress.

Stay up to date with news, announcements, and more, by seeing our latest press releases and media coverage.

Media CoveragePress Releases

Careers at Carisma

Our team is growing, and we want you to be a part of it. Be sure to check out our latest job openings.

If you’re dedicated to cutting edge science in healthcare, we want to hear from you.

Join Our Team